Home

Genprex, Inc. - Common Stock (GNPX)

0.2950
+0.0649 (28.21%)
NASDAQ · Last Trade: Apr 2nd, 11:19 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.2301
Open0.2400
Bid0.3894
Ask0.3900
Day's Range0.2400 - 0.3847
52 Week Range0.2200 - 4.090
Volume46,182,610
Market Cap17.53M
PE Ratio (TTM)-2.458
EPS (TTM)-0.1
Dividend & YieldN/A (N/A)
1 Month Average Volume5,647,106

About Genprex, Inc. - Common Stock (GNPX)

Genprex Inc is a biotechnology company focused on developing innovative gene therapy treatments for cancer and diabetes. Their primary aim is to enhance the efficacy of existing therapies and improve patient outcomes through the use of their proprietary Oncoprex immunogene therapy, which targets various types of tumors. The company is dedicated to advancing its promising treatments through clinical trials and aims to address significant unmet medical needs in oncology. With a strong emphasis on research and development, Genprex seeks to create transformative therapies that can benefit patients and improve their quality of life. Read More

News & Press Releases

Curious about the stocks that are showing activity after the closing bell on Wednesday?chartmill.com
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · April 2, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · April 2, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · April 2, 2025
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 18, 2025
Looking Into Genprex's Recent Short Interestbenzinga.com
Via Benzinga · October 28, 2024
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · February 11, 2025
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?benzinga.com
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.
Via Benzinga · November 4, 2024
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · October 28, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · October 28, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 24, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 23, 2024
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 23, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · October 22, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · October 22, 2024
Dow Falls Over 150 Points; General Motors Tops Q3 Viewsbenzinga.com
Via Benzinga · October 22, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 22, 2024
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 22, 2024
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · October 21, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · October 21, 2024
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 21, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · October 16, 2024
Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
• Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes.
Via Get News · September 4, 2024
Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
• Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes in New Video Presentation.
Via Get News · August 22, 2024
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Resultsbenzinga.com
Via Benzinga · August 13, 2024
S&P 500 Gains 1%; Home Depot Earnings Top Viewsbenzinga.com
Via Benzinga · August 13, 2024